ArticleThe Journal of investigative dermatology2018
Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study.
Article in The Journal of investigative dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.Journal of the American Academy of Dermatology · 2020Guideline
- A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).The Journal of investigative dermatology · 2020Trial
- A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial).The Journal of investigative dermatology · 2020Trial
- Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania.Medicina (Kaunas, Lithuania) · 2026Article
- The co-impact of diabetes and psoriasis on mortality risk for all causes and specific causes.Scientific reports · 2025Article
- Cardiovascular disease risk in psoriatic disease: mechanisms and implications for clinical practice.Current opinion in rheumatology · 2025Review
- Psoriasis: an update on topical and systemic therapies.Australian prescriber · 2025Review
- Weight-Adjusted Waist Index, Psoriasis, and All-Cause Mortality: Findings from the NHANES 2003-2006 and 2009-2014.Clinical, cosmetic and investigational dermatology · 2025Article
- The prognostic impact of stress hyperglycemia ratio for all-cause mortality in patients with Psoriasis.Scientific reports · 2024Article
- Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.Dermatology and therapy · 2024Review
- Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis.Dermatologic clinics · 2024Review
- A case-control study: epigenetic age acceleration in psoriasis.Archives of dermatological research · 2024Article
- Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities.Journal of psoriasis and psoriatic arthritis · 2023Article
- Incidence and prevalence of psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in the Teleprimary Care (TPC®) clinical information system from 2010 to 2020: Classification: Epidemiology.The British journal of dermatology · 2022Article
- Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons Living with Psoriatic Disease.Journal of psoriasis and psoriatic arthritis · 2022Article
- Promises and pitfalls in implementation science from the perspective of US-based researchers: learning from a pre-mortem.Implementation science : IS · 2022Article
- Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study.Rheumatology (Oxford, England) · 2022Article
- New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.The Journal of investigative dermatology · 2021Review
- Optimizing the Treatment of Moderate-to-Severe Psoriasis in Older Adults.Drugs & aging · 2020Review
- Updates in Psoriasis Management: Based on selected presentations from Maui Derm 2020, January 25-29, 2020, Maui, Hawaii.The Journal of clinical and aesthetic dermatology · 2020Article
Corrections and comments
- Commented on by
- Erratum issuedAddendum.2018
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.